The startup develops a capsule sampling technology that passively collects small bowel luminal fluid to generate precision datasets from the gastrointestinal tract. This approach provides healthcare providers with direct access to targeted intestinal data, enhancing the diagnosis and treatment of gastrointestinal health issues.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GFFounders
Product
Problem
Current methods of assessing the gut microbiome rely on stool samples, which do not accurately represent the microbial composition and conditions of the small intestine, a critical site for nutrient absorption, immune function, and brain-gut interactions. This limitation hinders the development of targeted therapies for gastrointestinal disorders.
Solution
Nimble Science provides the SIMBA GI Platform, a capsule-based technology for collecting and preserving multi-omic fluid biopsies from the small intestine. The autonomously transiting capsule collects samples throughout the GI tract, enabling a more complete and accurate characterization of the gut microbiome compared to traditional stool analysis. The platform generates precision datasets that can be used to monitor treatment-induced changes, validate product-induced microbiome changes, advance fecal transplant-induced treatments, correlate multi-omic profiles with disease states, monitor disease progression or regression, and measure environmental and genetic influences on microbiome composition. This approach offers healthcare providers direct access to targeted intestinal data, enhancing the diagnosis and treatment of gastrointestinal health issues.
Target Audience
The primary target audience includes healthcare providers, researchers, and pharmaceutical companies focused on gastrointestinal health and the gut microbiome.
Features
- SIMBA capsule autonomously transits the GI tract to collect fluid biopsies.
- Capsule seals and preserves samples to maintain sample integrity.
- Multi-omic analysis provides comprehensive datasets.
- Data can be used to monitor treatment-induced changes.
- Data can be used to validate product-induced microbiome changes.
- Data can be used to advance fecal transplant-induced treatments.
- Data can be used to correlate multi-omic profiles with disease states.